Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHAMS-EV
- Development stage
- Unknown
- Lead developer
- CHA Biotech
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
CHAMS-EV is an investigational **allogeneic exosome-based therapy** being developed by CHA Biotech for regenerative indications including corneal diseases, burns, and interstitial cystitis. The product appears to be a cell-derived extracellular vesicle biologic intended to deliver reparative and regenerative paracrine signals to injured tissues rather than acting through a single defined molecular target. Based on the company pipeline information provided, CHAMS-EV is being advanced in **Phase 1/2** development as an off-the-shelf exosome therapy program.
- Other names
- allogeneic exosome therapyextracellular vesicle therapycell-derived biologic
Beyond the preview
Go deeper on CHAMS-EV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHAMS-EV.